Introduction Hypertrophic cardiomyopathy (HCM) is a myocardial disease, usually of genetic origin, characterized by increased left ventricular wall thickness unexplained by abnormal loading conditions. Dynamic left ventricular outflow tract (LVOT) obstruction occurs in approximately 70% of patients, either at rest or with provocation, and is closely associated with symptoms and adverse clinical outcomes., The relief of the obstructive gradient remains a major therapeutic goal in obstructive HCM. Mavacamten, a cardiac myosin inhibitor, has been shown to reduce LVOT gradients and […]

Abstract Historically, the role of exercise stress echocardiography in the management of hypertrophic cardiomyopathy has been neglected in clinical practice according to the analysis of the 2002 Guidelines of the American College of Cardiology/ American Heart Association, which recommended caution use of this methodology in patients with hypertrophic cardiomyopathy due to the risk of both cardiac arrhythmia and hemodynamic collapse on exertion. Exercise stress testing in patients with hypertrophic cardiomyopathy is currently part of the routine assessment of symptomatic patients […]